Cara Therapeutics Stock News

Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.

On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.

Regeneron (REGN) delivered earnings and revenue surprises of 28.29% and 7.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab

CVS Health (CVS) is expected to have seen a significant part of its specialty orders being placed digitally through Q4 months, with growth drivers being COVID testing, vaccines and omni-channel.

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.

Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.

Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.